Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Tetrabuthylammonium. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC22A1 | O15245 | 3/20 | 0.57 |
| ▸ | SLC22A2 | O15244 | 1/20 | 0.50 |
| ▸ | TP53 | P04637 | 2/20 | 0.46 |
| ▸ | TSHR | P16473 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.46 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.46 |
| ▸ | DNM1 | Q05193 | 4/20 | 0.42 |
| ▸ | RECQL | P46063 | 2/20 | 0.39 |
| ▸ | GLA | P06280 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.39 |
| ▸ | BLM | P54132 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Tetrabuthylammonium SCHEMBL27909856 | 0.98 | SLC22A1 (0.55) | SLC22A1SLC22A2TP53TSHRALDH1A1 | |
| Tetrabuthylammonium SCHEMBL23632806 | 0.98 | SLC22A1 (0.55) | SLC22A1SLC22A2TP53TSHRALDH1A1 | |
| Tetrabuthylammonium SCHEMBL24419 | 0.98 | SLC22A1 (0.60) | SLC22A1SLC22A2TP53TSHRALDH1A1 | |
| Tetrabuthylammonium SCHEMBL1756146 | 0.98 | SLC22A1 (0.60) | SLC22A1SLC22A2TP53TSHRALDH1A1 | |
| Tetrabuthylammonium SCHEMBL333475 | 0.95 | SLC22A1 (0.57) | SLC22A1SLC22A2TP53TSHRALDH1A1 | |
| Tetrabuthylammonium SCHEMBL10581121 | 0.95 | SLC22A1 (0.57) | SLC22A1SLC22A2TP53TSHRALDH1A1 | |
| Tetrabuthylammonium SCHEMBL1072246 | 0.95 | SLC22A1 (0.57) | SLC22A1SLC22A2TP53TSHRALDH1A1 | |
| Tetrabuthylammonium SCHEMBL2313513 | 0.95 | SLC22A1 (0.57) | SLC22A1SLC22A2TP53TSHRALDH1A1 | |
| Tetrabuthylammonium SCHEMBL7396013 | 0.95 | SLC22A1 (0.57) | SLC22A1SLC22A2TP53TSHRALDH1A1 | |
| Tetrabuthylammonium SCHEMBL9795117 | 0.95 | SLC22A1 (0.57) | SLC22A1SLC22A2TP53TSHRALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11453595-B2 | Pre-treatment coating composition and a method for producing the same | Talga Advanced Materials GmbH (DE) | 2022-09-27 | — | — | US | disclosed |
| EP-3941889-A1 | CERAMIC COMPOSITE | Adelan Limited (GB) | 2022-01-26 | — | — | EP | disclosed |
| US-20200239707-A1 | FUNCTIONALISED GRAPHENE COMPOSITION | Talga Technologies Limited (GB) | 2020-07-30 | — | — | US | disclosed |
| EP-3658498-A1 | FUNCTIONALISED GRAPHENE COMPOSITION | Talga Technologies Limited (GB) | 2020-06-03 | — | — | EP | disclosed |
| EP-3490933-A1 | PRE-TREATMENT COATING COMPOSITION AND A METHOD FOR PRODUCING THE SAME | Talga Advanced Materials GmbH (DE) | 2019-06-05 | — | — | EP | disclosed |
| US-20190161354-A1 | PRE-TREATMENT COATING COMPOSITION AND A METHOD FOR PRODUCING THE SAME | Talga Advanced Materials GmbH (DE) | 2019-05-30 | — | — | US | disclosed |
| WO-2019020999-A1 | FUNCTIONALISED GRAPHENE COMPOSITION | Talga Technologies Limited (GB) | 2019-01-31 | — | — | WO | disclosed |
| US-9566574-B2 | Catalyst mixtures | DIOXIDE MATERIALS, INC. (US) | 2017-02-14 | — | — | US | disclosed |
| US-8524905-B2 | Processes for preparing 6-(difluoromethoxy)[1]benzofuro[3,2-c]pyridine-9-carbaldehyde, a novel intermediate for the synthesis of PDE IV inhibitors | GLENMARK PHARMACEUTICALS S.A. (CH) | 2013-09-03 | — | — | US | disclosed |
| EP-2588647-A1 | NOVEL CATALYST MIXTURES | Dioxide Materials Inc. (US) | 2013-05-08 | — | — | EP | disclosed |
| US-20120308903-A1 | Novel Catalyst Mixtures | DIOXIDE MATERIALS, INC | 2012-12-06 | — | — | US | disclosed |
| WO-2012006240-A1 | NOVEL CATALYST MIXTURES | DIOXIDE MATERIALS, INC. (US) | 2012-01-12 | — | — | WO | disclosed |
| US-20100168151-A1 | NOVEL PROCESSES FOR PREPARING 6-(DIFLUOROMETHOXY)[1]BENZOFURO[3,2-C]PYRIDINE-9-CARBALDEHYDE, A NOVEL INTERMEDIATE FOR THE SYNTHESIS OF PDE IV INHIBITORS | GLENMARK PHARMACEUTICALS, S.A. (CH) | 2010-07-01 | — | — | US | disclosed |
| WO-2008142542-A2 | PROCESSES FOR PREPARING BENZOFURO [3, 2-C] PYRIDINE- 9-CARBALDEHYDE DERIVATIVES AS NOVEL INTERMEDIATES FOR THE SYNTHESIS OF PDE IV INHIBITORS | GLENMARK PHARMACEUTICALS, S.A. (US) | 2008-11-27 | — | — | WO | disclosed |
| US-6245777-B1 | SODIUM CHANNEL MODULATORS | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2001-06-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100168151-A1 | NOVEL PROCESSES FOR PREPARING 6-(DIFLUOROMETHOXY)[1]BENZOFURO[3,2-C]PYRIDINE-9-CARBALDEHYDE, A NOVEL INTERMEDIATE FOR THE SYNTHESIS OF PDE IV INHIBITORS | PDE4B, PDE4A, PDE4C | SLC22A1 4102/4885SLC22A2 4116/4885TP53 4756/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.